Binimetinib Added to Standard of Care Elicits Responses in Advanced GIST

July 20, 2020

In an interview with Targeted Oncology, Ping Chi, MD medical oncologist, Geoffrey Beene Junior Faculty chair, Memorial Sloan Kettering Cancer Center, discussed the phase 2 study of binimetinib in combination with imatinib in patients with untreated advanced GIST.

Case of A 68-Year-Old Man With Gastrointestinal Stromal Tumor

July 16, 2020

Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.

Ripretinib Shows Survival Benefit in Patients With GIST Who Crossed Over After Progression in Phase 3 Study

July 06, 2020

“The data presented today further reinforce the potential of ripretinib to provide meaningful clinical benefit to patients with advanced gastrointestinal stromal tumor."

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 01, 2020

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

Ripretinib Receives FDA Approval for Treatment of Advanced GIST

May 15, 2020

"Today’s approval of Qinlock establishes a new standard of care for patients who have received three prior therapies."

FDA Denies Approval of Avapritinib in Fourth-Line GIST

May 15, 2020

The New Drug Application for avapritinib as treatment of unresectable or metastatic fourth-line gastrointestinal stromal tumor was refused by the FDA, according to a recently issued complete response letter.

Avapritinib Falls Short in Third- and Fourth-Line Gastrointestinal Stromal Tumors

April 28, 2020

"While we are disappointed by the outcome of the VOYAGER trial, we are deeply grateful to the patients, investigators, and clinical site staff who contributed to the completion of this global study."

How Ripretinib's Mechanism of Action Works in Patients With GIST

April 24, 2020

Margaret von Mehren, MD, discusses ripretinib and how it works in patients with heavily pretreated advanced gastrointestinal stromal tumors.

Cetuximab Plus Chemotherapy Worsens Survival in Resectable Colorectal Liver Metastases

March 24, 2020

Despite demonstrating improvement in overall survival as treatment of patients with advanced inoperable metastatic colorectal cancer, cetuximab plus chemotherapy led to significantly worse survival for patients with operable colorectal liver metastases in the perioperative setting, according to findings from randomized phase III clinical trial.

FDA Grants Priority Review to Ripretinib for Treatment of Advanced GIST

February 13, 2020

The FDA has granted Priority Review to the New Drug Application for ripretinib as treatment of patients with advanced gastrointestinal stromal tumors. This potential FDA approval has a Prescription Drug User Fee Act target action date of August 13, 2020, according to a press release from Deciphera Pharmaceuticals, Inc.